Overview

The governing structure of PrECOG is comprised of a Board of Managers, including a Chair/CEO, Director of Operations, and 5 physician members drawn from the ECOG-ACRIN Cancer Research Group leadership and academic teams. All are prominent thought leaders within ECOG-ACRIN Cancer Research Group, and in their institutions of primary affiliation.

PrECOG’s clinical trial sites represent an established network of institutions, many with master service agreements that facilitate study start-up activities, thus providing the leverage of strong existing site relationships that foster high-quality performance.

PrECOG offices are conveniently located in Center City, Philadelphia, a city rich in history, culture, and dining options. Our offices are easily accessible by rail, air, or car.

 

Our Leadership

Our Operations team is made up of a group of experienced project management, regulatory, statistical, monitoring, and support personnel.

Peter O’Dwyer, MD
Peter O’Dwyer, MD
CEO and Chair

Peter O’Dwyer, MD

CEO and Chair

Dr. O’Dwyer is the PrECOG LLC Board of Managers Chair and CEO. He is a medical oncologist at the University of Pennsylvania, where he holds an appointment as Professor of Medicine. His research focus is in the area of novel therapy development primarily in pancreatic and colorectal cancers.  He leads the GI committee, and since 2017 has served as Group Co-Chair for the ECOG-ACRIN Cancer Research Group.

Donna Marinucci
Donna Marinucci
Director of Operations

Donna Marinucci

Director of Operations

Donna M. Marinucci serves on the PrECOG Board of Managers and has oversight for study start and management. She is the Executive Director ECOG-ACRIN Cancer Research Group. She is also Vice President for the Coalition of Cancer Cooperative Groups and its subsidiary, Alpha Oncology. Her overall career in oncology research in the academic management space has spanned over 25 years.

Board of Managers

Al Benson, MD
Al Benson, MD

Al Benson, MD

Dr. Benson is a professor of medicine in Hematology/Oncology at Northwestern University Feinberg School of Medicine and associate director for Cooperative Groups at Robert H. Lurie Comprehensive Cancer Center. At ECOG-ACRIN, he is a member of the Principal Investigators’ Committee, and co-chair of both the NCORP Advisory Committee and Cancer Care Delivery Research Committees. He chairs the Therapeutic and PrECOG DSMC. His primary research focus is gastrointestinal cancers.

Bruce Giantonio, MD
Bruce Giantonio, MD

Bruce Giantonio, MD

Bruce J. Giantonio, MD, is a medical oncologist at the Massachusetts General Hospital and an Associate Professor of Medicine at the Harvard Medical School. Dr. Giantonio also serves as the Executive Officer for the ECOG-ACRIN Cancer Research Group.

Joseph Sparano, MD
Joseph Sparano, MD

Joseph Sparano, MD

Dr. Joseph Sparano is Professor of Medicine & Women’s Health at the Albert Einstein College of Medicine, Associate Chairman in the Department of Oncology at Montefiore Medical Center, and Associate Director for Clinical Research at the Albert Einstein Cancer Center. He is a medical oncologist whose research has focused on developmental therapeutic approaches for breast cancer and HIV-associated cancers, and clinical application biomarkers in breast cancer.

Patrick Flynn, MD
Patrick Flynn, MD

Patrick Flynn, MD

Patrick Flynn, MD was past principal investigator of the Metro Minnesota Community Cooperative Oncology Research Consortium [previously Metro-Minnesota CCOP]. He is a board member of the ECOG-ACRIN Research Foundation and past co-chair of the ECOG-ACRIN Cancer Research Group Community Cancer Committee.

Suresh Ramalingam, MD
Suresh Ramalingam, MD

Suresh Ramalingam, MD

Dr. Ramalingam is Professor of Hematology and Medical Oncology and the Assistant Dean for Cancer Research at the Emory University School of Medicine. He is also the Roberto C. Goizueta Chair for Cancer Research and the Deputy Director of the Winship Cancer Institute of Emory University. Dr. Ramalingam’s specialty is Thoracic Oncology.

What PrECOG Offers

Research Development

Ideas for PrECOG clinical trials generally arise from the ECOG-ACRIN Cancer Research Group Scientific Committees and can be proposed by the committee, individual committee members, or via a collaborative relationship with industry partners or other research companies. PrECOG studies generally aim to align with, expand and support the goals of the ECOG-ACRIN Cancer Research Group executive leadership.

To inquire further about research collaborations please contact PrECOG.

Research Support

Identifying tumor biomarkers and genetic/genomic signatures has led to a revolution in cancer care, allowing the oncologist to target specific treatments to those patients most likely to respond. Thus, exploring additional markers for patient selection or tumor response to investigational therapy is of primary importance in clinical trial design and evaluation. PrECOG utilizes central laboratories for consistency in tissue banking and correlative biomarker and patient imaging evaluations.

 

To inquire further about research collaborations, please contact PrECOG.

PrECOG Study Sites

PrECOG sites currently include representation from U.S. and international research networks, community and NCI-designated cancer centers, academic institutions, and individual research practices with a depth of oncology research experience. These sites are members of ECOG-ACRIN Cancer Research Group and NCTN and many have master agreements  with PrECOG which can facilitate study activation.

Go to Trials

Study Operational Oversight

The PrECOG Operations Team provides oversight and monitoring of all studies to ensure patient safety, data integrity, and data validity. Clinical trial oversight is determined by the nature of any collaboration, but is commensurate with the anticipated safety risks, size and complexity of the clinical trial. Study management standards include central registration/randomization and electronic data capture (EDC). Study systems and supporting materials are developed to meet all known ICH and GCP requirements.

If determined that the study requires independent data safety monitoring oversight, the PrECOG Global Data and Safety Monitoring Board (DSMB) can monitor subject safety, scientific integrity of the clinical trial and data validity. The DSMB may also monitor accrual against timelines, the quality of data collection and management, and other outcomes.